| Autor: |
Autenrieth, M., Horn, T., Kurtz, F., Nguyen, K., Morgenstern, A., Bruchertseifer, F., Schwaiger, M., Blechert, M., Seidl, C., Senekowitsch-Schmidtke, R., Gschwend, J., Scheidhauer, K., Autenrieth, M E, Gschwend, J E |
| Předmět: |
|
| Zdroj: |
Der Urologe A; Jan2017, Vol. 56 Issue 1, p40-43, 4p |
| Abstrakt: |
Background: In failure to respond to bacillus Calmette-Guérin (BCG) in patients with carcinoma in situ (CIS) of the urinary bladder, radical cystectomy remains the mainstay after BCG failure.Objectives: The aim of this pilot study was to evaluate tolerability and safety of the α‑emitter radioimmunoconjugate instillation in patients after BCG failure.Materials and Methods: Nine patients were included. After emptying the bladder via a transurethral catheter, Bi-213-anti-EGFR-mAb was instilled. Treatment was terminated by emptying of the radioimmunoconjugate from the bladder 120 min after instillation. Efficacy was evaluated via endoscopy and histology 6 weeks after instillation.Results: All patients showed excellent toleration of the treatment without any side effects. Treatment resulted in complete eradication of tumor cells in 3 patients and persistent tumor detection in the other 6 patients.Conclusions: Intravesical instillation of Bi-213-anti-EGFR-mAb is a promising therapeutic option for treatment of in situ bladder cancer after BCG failure for patients who wish to preserve the bladder. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink